Summary & Overview
CPT 81508: PAPP–A and hCG Laboratory Assay with Algorithmic Risk Score
CPT code 81508 identifies a laboratory assay and algorithmic analysis that measures PAPP–A and hCG protein levels and combines those results with patient data to generate a reported risk score. This service represents the integration of biochemical measurement and software-driven risk modeling and is relevant to prenatal risk assessment and other clinical risk-stratification contexts. Nationally, the code matters because it distinguishes a combined laboratory-and-algorithm service from standalone analyte testing or separate interpretation services, affecting billing, coverage, and quality reporting.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for the assay, typical sites of service, and the service model under which the technical testing and algorithmic reporting occur. The publication also summarizes benchmarks for utilization and coverage constructs, outlines common modifiers associated with reporting the service, and highlights policy and coding considerations that influence reimbursement and payer review. Intended takeaways include clarity on what CPT code 81508 represents, where it is performed, and the major topics stakeholders consider when assessing coverage and claims for combined laboratory-and-algorithm tests.
Billing Code Overview
CPT code 81508 describes a laboratory service in which the lab analyst measures two serum proteins, pregnancy-associated plasma protein A (PAPP–A) and human chorionic gonadotropin (hCG), and applies an algorithmic analysis that integrates those assay results with patient data to generate and report a patient risk score. The primary service type is laboratory-based biomarker testing with algorithmic risk assessment. The typical site of service is a clinical laboratory or an independent diagnostic testing facility (IDTF) where blood specimens are collected and processed and algorithmic software is applied to produce the reported risk score.
Clinical & Coding Specifications
Clinical Context
A 12-week pregnant patient presents for first-trimester aneuploidy screening. The clinician orders maternal serum biochemical testing for pregnancy-associated plasma protein A (PAPP‑A) and free ß‑human chorionic gonadotropin (hCG) as part of a combined screening algorithm incorporating maternal age, gestational age, and ultrasound findings (nuchal translucency if available). A phlebotomy technician collects a maternal blood specimen at an outpatient laboratory or hospital outpatient drawing station. The specimen is routed to a reference laboratory where a clinical lab analyst performs the immunoassays for PAPP-A and hCG, validates assay performance, and enters patient demographic and clinical data into the lab information system. The laboratory information system applies a validated algorithm to integrate analyte concentrations with maternal age and gestational age to generate a patient-specific risk score for trisomy 21 and trisomy 18. The laboratory issues a structured report to the ordering obstetric clinician and uploads results to the electronic medical record. Typical sites of service include outpatient hospital laboratories, independent reference laboratories, and large ambulatory clinic laboratories. The service type is clinical laboratory testing with algorithmic risk calculation performed by the lab technical staff and reported as a combined biochemical screening result represented by CPT 81508.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|